Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785849 | Cancer Treatment Reviews | 2018 | 24 Pages |
Abstract
Gene expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last decade, 4 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched [HER2-E] and Basal-like) have been identified and intensively studied. In this article, we review and discuss the clinical implications of the 2 non-luminal subtypes (i.e. HER2-E and Basal-like) identified within hormone receptor (HR)-positive disease. After reviewing 32 studies for a total of 13,091 samples, â¼8% andâ¯â¼â¯15% of early and metastatic HR+/HER2-negative breast cancer, respectively, were found to be non-luminal. Clinically, HR+/HER2-negative/non-luminal subtypes have been associated with estrogen independence, chemo-sensitivity, resistance to CDK4/6 inhibition and poor outcome. Interestingly, EGFR/HER2 tyrosine kinase inhibition might be of value in the HR+/HER2-negative/HER2-E subtype. Finally, the HER2-E subtype within HR+/HER2â¯+â¯disease representsâ¯â¼â¯30% and has been associated with anti-HER2 sensitivity, chemo-sensitivity and resistance to CDK4/6 inhibition. In the upcoming years, retrospective and prospective clinical trials evaluating both biomarkers should lead to improvements in patient outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Juan Miguel Cejalvo, Tomás Pascual, Aranzazu Fernández-MartÃnez, Fara Brasó-Maristany, Roger R. Gomis, Charles M. Perou, Montserrat Muñoz, Aleix Prat,